Clinical Trial

A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 3, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial is a late phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, safety, and pharmacokinetics of KDT-3594 administered at escalating doses ranging from 0.25 to 2 mg per day for 17 weeks in patients with advanced PD with levodopa.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-03.
Status change: Recruiting → Active, Not Recruiting 2026-02-27
Trial Details
NCT Number NCT06722729
Lead Sponsor Kissei Pharmaceutical Co., Ltd.
Conditions Parkinson Disease
Enrollment 150 participants
Start Date 2024-12-16
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2026-03-03